Investors and analysts reacted immediately to Novo's revelation. The price of Novo's common stock declined dramatically. From ...

In a report released today, Jo Walton from UBS maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price target of ...

On an adjusted basis, the U.S. drugmaker expects to earn between $22.50 and $24.00 per share in 2025. Analysts were expecting ...

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

The post contains 50 new customer stories, which appear at the beginning of each section of customer lists. The post will be ...

Trademark prosecution data reveals how the rival healthcare companies are ensuring exclusivity internationally for their ...